# Efficacy of Interleukin-2 in Triple Negative Breast Cancer

> **NCT05821686** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nova Scotia Health Authority** · enrollment: 10 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Human Interleukin-2 (IL-2) (Proleukin)

## Key facts

- **NCT ID:** NCT05821686
- **Lead sponsor:** Nova Scotia Health Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-02
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821686, "Efficacy of Interleukin-2 in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05821686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*